Trials / Completed
CompletedNCT02439385
Avastin/FOLFIRI in Combination With Curcumin in Colorectal Cancer Patients With Unresectable Metastasis
First Line Avastin/FOLFIRI in Combination With Curcumin-containing Supplement in Colorectal Cancer Patients With Unresectable Metastasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Gachon University Gil Medical Center · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
Oral curcumin-containing supplement will be given to colorectal cancer patients with unresectable metastases who will be starting Avastin/FOLFIRI chemotherapy for up to completion of (or withdrawal from) chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avastin/FOLFIRI | Avastin: 5mg/kg iv on day1, every 14 days. Irinotecan: 180 mg /m2 iv on day1, every 14 days. Leucovorin: 200 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil bolus: 400 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil infusion: 1200 mg/m2 iv on day1,2 every 14 days. |
| DIETARY_SUPPLEMENT | Curcumin | Dietary supplement of nanostructured lipid curcumin particle 100mg po bid daily |
Timeline
- Start date
- 2015-08-24
- Primary completion
- 2019-08-01
- Completion
- 2019-08-01
- First posted
- 2015-05-08
- Last updated
- 2022-03-31
Source: ClinicalTrials.gov record NCT02439385. Inclusion in this directory is not an endorsement.